Skip to content
Review Open access

Results from a multisite quality improvement initiative in solid tumor precision medicine.

Oct 2026 · JCO Oncology Practice · 0 citations

Abstract

582 Background: Timely, comprehensive biomarker testing is essential to identify actionable genomic alterations and guide targeted therapy in patients with advanced solid tumors. However, community and academic cancer centers often encounter delays in ordering, prolonged turnaround from diagnosis to results, and gaps before initiating targeted therapy. We conducted a multisite quality improvement (QI) initiative to address these gaps in precision oncology care. Methods: Three cancer centers from the states of Georgia, Kansas, and Ohio participated in a guided initiative that included live and enduring accredited education (CME) and QI coaching. After baseline chart review and practice assessment, each site completed CME, facilitated QI meetings, and Plan-Do-Study-Act (PDSA) cycles to develop process improvements. Interventions included standardized biomarker testing workflows, computerized order entry with EHR integration, reflex and complementary tissue/ctDNA testing protocols, and expanded nurse navigator roles for tracking orders and results. Pre- and post-intervention chart data were compared across all sites. Results: The proportion of patients with biomarker test orders within 4 weeks of diagnosis improved from 42.1% (48/114) to 62.6% (67/107) for solid tumors (+20.5%) and from 44.1% (26/59) to 96.0% (48/50) for NSCLC (+51.9%). Median time from diagnosis to complete biomarker test results decreased from 128.2 to 24.7 days (103.5 day reduction) for solid tumors, and from 55.7 to 19.3 days (36.4 day reduction) for NSCLC. Median time from test result to start of targeted therapy decreased from 102 to 38.5 days (63.5 day reduction) for solid tumors and from 99.5 to 29 days (70.5 day reduction) for NSCLC. Learner competency significantly improved (P < .001) among all learners in 7 measured learning objectives with CME. For example, learners improved their ability to implement a timely biomarker testing process (from 50% at baseline to 94% after education), to accurately interpret biomarker results and select optimal targeted therapy for patients with NSCLC (from 61% to 93%), and to select appropriate molecular testing to guide treatment decisions for patients with CRC (from 48% to 94%). Conclusions: A structured multisite QI initiative produced clinically meaningful improvements in the timeliness of biomarker testing and targeted therapy initiation across diverse cancer centers. Standardized testing workflows, computerized order entry, and expanded nurse navigator roles were key drivers of improvement. Sites established sustainment mechanisms, including navigator ownership, automated EHR reporting, and ongoing governance review. An implementation toolkit was developed to support spread to additional settings. These findings suggest that locally adapted process changes can substantially reduce delays in precision oncology care and optimize patient care.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.